Biggest news of the week may this morning in the announcement of of health and human services through definitive rules under the new health care law dictate how health insurance companies must spend rewards collecting Department.
The anticipated suspense and much-discussed provisions on medical claims so-called is presented.According to the law, insurers must spend at least 80 cents of every premium dollar that improving the welfare of their Kunden.Der rest goes to administrative costs, including profits.
"Expect much analysis (and spin), mean what the final regulations on the industry and buyers of health insurance.""Thanks to the affordable care Act, millions of Americans better value for your health insurance premium dollar received," said Kathleen Sebelius, Secretary of health and human services, in a press release.
"These new rules are an important step to account insurance companies and value for consumers increase drag."
Read more about the new rules can in the accompanying fact sheet and regulations itself.
Analysts expect the dread, on which the regulations might look will now disappear and investors with company stocks to make convenient.
But don't expect the drama full of many States will be - expected under the new law, relying on the possible disruption to your market forces each insurer is bitten.Infolgedessen to meet the new provisions for exemptions will be closely each to see which States step forward and how receptive federal regulators are exactly to your needs.
Mean the Thanksgiving holiday, it is relatively quiet on other fronts, with no food and Drug Administration Advisory Committee scheduled hearings for this week.
It is only a quarterly earnings report from Medtronic, the large medical devices manufacturers before the market Tuesday opens. during Rick wise, analyst at White rink Swann, the quarter thinks "low utilization and increasing pressure on prices will reflect" says he better than expected results could come out with the company.
If you missed it, could a provocative story in the Wall Street Journal on the States, contemplation dropping out of the Medicaid program (although the article really think you are) and my colleague Robert PEAR's want to check interesting piece on Sunday about the concerns that the warmth and blur to create alliances between hospitals and doctors to help you better serve out under the new health care law in a much less competitive health care system translate could.
Let us know if we missed something.
View the original article here
Cardiologist, not to mention Wall Street analysts, are the results of several important studies that meet at the American Heart Association this week presented closely monitor.
In particular, are on Monday morning bring researchers developed the results of the rocket AF a study that compared warfarin, Rivaroxaban, blutgerinnung retardant a new drug from Bayer and Johnson and Johnson to prevent strokes in patients with atrial fibrillation.
The question is not only whether the new pill worked as also warfarin, an older drug to take effective but often uncomfortable for patients, but the new drug was how secure when compared to the older drug caused bleeding.
Johnson and Johnson has a Ð food and Drug Administration to approve that for any other purpose - to reduce the risk of large blood clots Rivaroxaban in people the knee or hip replacement surgery are subject to.
But the f.d.a has already approved the first new generation alternative to warfarin. Pradaxa, also known under its chemical name, made by Boehringer Ingelheim, Dabigatran Agency received approval last month as stroke prevention treatment for people with atrial fibrillation.
Meanwhile researchers will present on Wednesday morning, expected that define a study called includes Anacetrapib, cholesterol-Medikament in the development of Merck.It is designed to increase HDL, also known as "good" cholesterol while reducing LDL, also known as "bad" cholesterol.
The meeting continue through Wednesday in Chicago.Can developments in one of my favorite blogs, Larry of cough's CardioBrief or by his Twitter feed @ Cardiobrief follow.
Heart lovers cardiologist, Dr. Harlan Krumholz, the Yale should follow their Twitter feed @ Hmkyale is.
On Monday's Kathleen Sebelius Secretary of health and human services planned the keynote speech at the annual meeting of the National Business Coalition of health liefern.Die non profit group around the country representing more than 7,000 employers, including the implication of the law, discuss employers health overhaul.
About are the f.d.a it a busy week for external experts on Advisory Committee panels, to check the industrial applications for new drugs.
On Tuesday, this is arthritis advisory panel, Benlysta, a human monoclonal antibody of Human Genome Sciences, for the treatment of patients with Lupus prüfen.Am discuss a regulatory path for potential anthrax-Impfstoffe Tuesday the vaccine Advisory Committee and Wednesday, which consider same group approval for Gardasil that Merck to include prevention of anal cancer vaccine of HPV is erweitern.Inzwischen Thursday the Agency plastic surgery Panel, a new handheld device called MelaFind as a system to detect, predict whether moles and skin lesions cancerous device shall be checked.
Towards the end of the week, kidney specialists become aware of developments of the meeting of the American Society of Nephrology in Denver, where late-breaking clinical trials are due will be presented on Saturday.
In particular, presents researcher at Oxford University the results Of the sharp study, one Merck-sponsored study the effectiveness of the use of cholesterol treatments simvastatin and Ezetimibe, also known as the combination tested pill Vytorin on cardiovascular events in patients with chronic kidney disease.
If you want to nominate your favorite blog or Twitter on developments feed in the treatment of kidney disease, please send us a note.
Correction: An earlier version of this post wrong type of specialists who most closely monitor the American Society of Nephrology Conference in Denver running.make are not liver, kidney, specialists.
View the original article here
